Needham & Company LLC Issues Positive Forecast for Pulse Biosciences (NASDAQ:PLSE) Stock Price

Pulse Biosciences (NASDAQ:PLSE) had its price target increased by Needham & Company LLC from $58.00 to $64.00 in a report released on Friday,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms also recently weighed in on PLSE. Oppenheimer lifted their price target on shares of Pulse Biosciences from $35.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, October 13th. Mizuho set a $55.00 price objective on shares of Pulse Biosciences in a research report on Tuesday, October 13th. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, October 15th. Finally, Canaccord Genuity Group upped their price target on Pulse Biosciences from $43.00 to $58.00 and gave the stock a “buy” rating in a research note on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pulse Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.60.

Pulse Biosciences Price Performance

Shares of Pulse Biosciences stock traded up $0.22 on Friday, hitting $53.29. 428,197 shares of the company’s stock traded hands, compared to its average volume of 373,557. The company has a fifty day moving average of $51.55 and a two-hundred day moving average of $32.28. Pulse Biosciences has a one year low of $12.56 and a one year high of $58.90. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of -44.04 and a beta of 1.65.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.01). The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.52 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. Pulse Biosciences’s quarterly revenue was down 54.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.29) earnings per share. Equities research analysts anticipate that Pulse Biosciences will post -1.34 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Liane Teplitsky bought 1,001 shares of Pulse Biosciences stock in a transaction dated Tuesday, September 1st. The stock was purchased at an average cost of $49.95 per share, with a total value of $49,999.95. Following the transaction, the chief operating officer directly owned 4,095 shares of the company’s stock, valued at approximately $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have bought a total of 4,095 shares of company stock valued at $199,931 over the last 90 days. Insiders own 74.00% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Pulse Biosciences in the second quarter worth $40,672,000. Bank of America Corp DE bought a new position in shares of Pulse Biosciences during the 2nd quarter worth $40,115,000. Panoramic Capital LLC bought a new position in shares of Pulse Biosciences during the 2nd quarter worth $2,719,000. Bank of New York Mellon Corp bought a new position in shares of Pulse Biosciences during the 2nd quarter worth $1,196,000. Finally, Formula Growth Ltd. purchased a new stake in Pulse Biosciences in the 2nd quarter worth about $832,000. Institutional investors own 76.95% of the company’s stock.

Key Stories Impacting Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Six-month interim results from the PRECISE-BTN study of Pulse’s nano-pulsed field ablation treatment for thyroid nodules were described as positive. The update adds clinical evidence for the technology. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results Article: Six-Month PRECISE-BTN Study Results
• Positive Sentiment: Canaccord Genuity raised its price target from $58 to $74 and maintained a Buy rating; Needham also reiterated Buy and raised its target from $58 to $64. These higher targets reflect improved analyst expectations. Canaccord Genuity recommendations Needham recommendations
• Positive Sentiment: The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule—progress toward advancing its technology. Business updates and Q3 results
• Negative Sentiment: Pulse plans a 15%–25% increase in quarterly non-GAAP expenses as it works toward a Q4 2027 CE Mark target. The added spending could weigh on cash use and future losses. Expense outlook and CE Mark target
• Negative Sentiment: Q3 revenue was $400,000, below the approximately $521,000 estimate and down 54.1% year over year. The $0.32 per-share loss was also slightly wider than the $0.31 consensus loss, underscoring the company’s limited current revenue base. Q3 results coverage

Pulse Biosciences Company Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.